Meiji Holdings Co., Ltd. (MEJHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Meiji Holdings Co., Ltd. (MEJHF) with AI Score 54/100 (Hold). Meiji Holdings Co. , Ltd. is a diversified food and pharmaceutical company based in Japan, with a global presence. Market cap: 0, Sector: Consumer defensive.
Last analyzed: Mar 16, 2026Meiji Holdings Co., Ltd. (MEJHF) Consumer Business Overview
Meiji Holdings Co., Ltd. is a Japanese consumer defensive company with a diversified portfolio of food and pharmaceutical products. Operating in both domestic and international markets, the company leverages its established brands and distribution networks to maintain a competitive position in the packaged foods and healthcare sectors, with a focus on innovation and quality.
Investment Thesis
Meiji Holdings presents a stable investment profile within the consumer defensive sector, supported by its diversified product portfolio and established market presence. With a P/E ratio of 23.53 and a dividend yield of 2.57%, the company offers a blend of value and income potential. A low beta of 0.10 indicates lower volatility compared to the broader market. Growth catalysts include expansion in international markets and continued product innovation, particularly in the nutritional and pharmaceutical segments. Potential risks include fluctuations in raw material costs and evolving regulatory landscapes in the pharmaceutical industry. The company's 4.0% profit margin and 30.2% gross margin reflect its ability to maintain profitability in a competitive environment.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $5.49 billion reflects Meiji's significant presence in the consumer defensive sector.
- P/E ratio of 23.53 indicates a valuation in line with the packaged foods industry.
- Profit margin of 4.0% demonstrates the company's ability to generate earnings from its diverse product portfolio.
- Gross margin of 30.2% showcases efficient cost management in manufacturing and distribution.
- Dividend yield of 2.57% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio across food and pharmaceutical sectors.
- Strong brand recognition and customer loyalty in Japan.
- Extensive distribution network and established market presence.
- Commitment to research and development.
Weaknesses
- Reliance on the Japanese market for a significant portion of revenue.
- Exposure to fluctuations in raw material costs.
- Limited presence in some international markets.
- Profit margins could be higher compared to some competitors.
Catalysts
- Ongoing: Expansion into new international markets, particularly in Asia, driving revenue growth.
- Ongoing: Product innovation in functional foods and pharmaceuticals, catering to evolving consumer preferences.
- Upcoming: Potential strategic acquisitions to expand market share and product offerings.
- Ongoing: Growth in e-commerce channels, enhancing customer engagement and online sales.
- Ongoing: Continued investment in research and development, leading to new product launches and technological advancements.
Risks
- Ongoing: Intense competition from other food and pharmaceutical companies, impacting market share and profitability.
- Potential: Fluctuations in raw material costs, affecting gross margins.
- Potential: Changing consumer preferences and health trends, requiring adaptation and innovation.
- Ongoing: Stringent regulations and compliance requirements in the pharmaceutical industry, increasing costs and complexity.
- Potential: Economic downturns affecting consumer spending and demand for discretionary products.
Growth Opportunities
- Expansion in Asian Markets: Meiji has the opportunity to further expand its presence in high-growth Asian markets, particularly in Southeast Asia and India. These regions offer increasing consumer spending power and a growing demand for packaged foods and nutritional products. By tailoring its product offerings to local tastes and preferences, Meiji can capture a larger share of these markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- Product Innovation in Functional Foods: The increasing consumer focus on health and wellness presents a significant opportunity for Meiji to develop and market functional foods with added health benefits. This includes products fortified with vitamins, minerals, and probiotics. By investing in R&D and collaborating with research institutions, Meiji can create innovative products that meet the evolving needs of health-conscious consumers. The global functional foods market is projected to reach $278 billion by 2028.
- Pharmaceutical Segment Growth: Meiji's pharmaceutical segment can drive growth through the development and commercialization of new drugs, particularly in areas such as infectious diseases and central nervous system disorders. Strategic partnerships with other pharmaceutical companies and research institutions can accelerate the drug development process. The global pharmaceutical market is expected to reach $1.7 trillion by 2027, providing ample opportunity for Meiji to expand its pharmaceutical business.
- E-commerce Channel Development: Investing in and expanding its e-commerce channels will allow Meiji to reach a broader customer base and capitalize on the growing trend of online shopping. By developing user-friendly online platforms and offering convenient delivery options, Meiji can enhance customer engagement and drive sales. The global e-commerce market is projected to reach $6.4 trillion in 2024, highlighting the significant potential for online sales growth.
- Strategic Acquisitions: Meiji can pursue strategic acquisitions of smaller companies with complementary product portfolios or technologies. This can help Meiji expand its market share, diversify its product offerings, and gain access to new geographic markets. Careful due diligence and integration planning are essential to ensure the success of these acquisitions. The mergers and acquisitions market in the food and beverage industry remains active, providing opportunities for Meiji to grow through strategic acquisitions.
Opportunities
- Expansion in high-growth Asian markets.
- Development of innovative functional foods and pharmaceuticals.
- Strategic acquisitions to expand market share and product offerings.
- Growth in e-commerce channels to reach a broader customer base.
Threats
- Intense competition from other food and pharmaceutical companies.
- Changing consumer preferences and health trends.
- Stringent regulations and compliance requirements in the pharmaceutical industry.
- Economic downturns affecting consumer spending.
Competitive Advantages
- Strong brand reputation and customer loyalty built over a century of operations.
- Diversified product portfolio spanning food and pharmaceutical industries.
- Extensive distribution network in Japan and international markets.
- Commitment to research and development, leading to innovative products and technologies.
About MEJHF
Founded in 1916 and headquartered in Tokyo, Japan, Meiji Holdings Co., Ltd. has evolved into a diversified conglomerate operating in the food and pharmaceutical industries. Initially focused on dairy products, the company expanded its offerings to include a wide array of confectioneries, nutritional products, and pharmaceuticals. The Food segment provides yogurt, cheese, milk, beverages, ice cream, chocolates, and nutritional supplements. The Pharmaceutical segment develops and markets drugs for infectious diseases and central nervous system disorders, as well as veterinary drugs and vaccines. Meiji's geographic reach extends beyond Japan, with a growing presence in international markets. The company emphasizes research and development to create innovative products that cater to changing consumer needs and preferences. Its commitment to quality and safety has helped build strong brand loyalty. Meiji's integrated business model, encompassing manufacturing, distribution, and marketing, allows it to maintain control over its supply chain and ensure product integrity. The company's focus on both human and animal health positions it uniquely within the consumer defensive sector.
What They Do
- Manufactures and sells dairy products such as yogurt, cheese, and milk.
- Produces a variety of confectioneries including chocolates, gummy products, and chewing gums.
- Offers nutritional products such as sports nutrition supplements and infant formula.
- Develops and markets pharmaceuticals for infectious diseases and central nervous system disorders.
- Provides veterinary drugs for livestock and fisheries.
- Offers OTC medicines and beauty supplements.
- Manufactures feed stuffs, corn sweeteners, and sugar.
- Provides transportation and distribution services.
Business Model
- Manufacturing and selling a wide range of food products, including dairy, confectionery, and nutritional items.
- Developing and commercializing pharmaceutical products for human and animal health.
- Generating revenue through direct sales to consumers and distribution through retail channels.
- Investing in research and development to create innovative products and improve existing offerings.
Industry Context
Meiji Holdings operates in the consumer defensive sector, specifically within the packaged foods and pharmaceutical industries. The packaged foods market is characterized by stable demand and consistent growth, driven by population increases and changing consumer preferences. The pharmaceutical industry is subject to stringent regulations and high R&D costs but offers significant growth potential through innovative drug development. Meiji competes with other major players in the food and pharmaceutical sectors, leveraging its brand reputation and diversified product offerings to maintain its market position.
Key Customers
- Consumers who purchase dairy products, confectioneries, and nutritional supplements.
- Healthcare providers who prescribe and administer pharmaceutical products.
- Livestock and fisheries farmers who use veterinary drugs and feed products.
- Retailers and distributors who sell Meiji's products to end consumers.
Financials
Chart & Info
Meiji Holdings Co., Ltd. (MEJHF) stock price: Price data unavailable
Latest News
-
Japan’s Meiji books another impairment on China food business
Yahoo! Finance: MEJHF News · Mar 25, 2026
-
Meiji to invest in Hello Panda production in US
Yahoo! Finance: MEJHF News · Mar 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEJHF.
Price Targets
Wall Street price target analysis for MEJHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates MEJHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Katsunari Matsuda
CEO
Katsunari Matsuda serves as the CEO of Meiji Holdings Co., Ltd., leading a workforce of over 17,000 employees. His career within Meiji spans several decades, during which he has held various leadership positions across different divisions. Matsuda's expertise lies in strategic planning, business development, and operational management. He is known for his focus on innovation, quality, and sustainable growth. Matsuda holds a degree in Business Administration from a leading Japanese university.
Track Record: Under Katsunari Matsuda's leadership, Meiji Holdings has expanded its presence in international markets and launched several successful new products. He has overseen significant investments in research and development, leading to advancements in both the food and pharmaceutical segments. Matsuda has also focused on improving operational efficiency and reducing costs, contributing to the company's profitability. His strategic decisions have helped Meiji maintain its competitive position in a challenging market environment.
MEJHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Meiji Holdings Co., Ltd. has not met the requirements for the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in MEJHF.
- Low trading volume and liquidity can lead to price volatility.
- The OTC Other tier indicates a higher level of risk compared to companies listed on major exchanges.
- Potential for fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before making any investment decisions.
- Established operating history of over 100 years.
- Presence in the consumer defensive sector, which tends to be more stable.
- Diversified product portfolio spanning food and pharmaceutical industries.
- Global presence with operations in multiple countries.
- Commitment to research and development.
MEJHF Consumer Defensive Stock FAQ
What does Meiji Holdings Co., Ltd. do?
Meiji Holdings Co., Ltd. is a diversified company that operates primarily in the food and pharmaceutical industries. Through its Food segment, Meiji manufactures and sells a wide range of products, including dairy items like milk, yogurt, and cheese, as well as confectioneries such as chocolates and gummy candies. The Pharmaceutical segment focuses on developing and marketing drugs for infectious diseases and central nervous system disorders, along with veterinary drugs for livestock and companion animals. Meiji's integrated business model allows it to control its supply chain and maintain product quality, contributing to its strong brand reputation.
What do analysts say about MEJHF stock?
Analyst coverage of MEJHF is limited due to its OTC listing. However, the company's financial metrics, such as its P/E ratio of 23.53 and dividend yield of 2.57%, suggest a stable investment profile within the consumer defensive sector. Growth considerations include the company's expansion in international markets and its focus on product innovation. Investors should conduct their own thorough research and consider the risks associated with investing in OTC securities before making any investment decisions. The AI analysis is currently pending.
How does Meiji Holdings Co., Ltd. adapt to changing consumer preferences?
Meiji Holdings Co., Ltd. adapts to changing consumer preferences through continuous product innovation and market research. The company invests in research and development to create new products that meet evolving consumer needs, such as functional foods with added health benefits and innovative confectionery items. Meiji also monitors consumer trends and preferences through market research and feedback, allowing it to adjust its product offerings and marketing strategies accordingly. This proactive approach helps Meiji maintain its competitive edge and cater to the changing demands of the market.
What is Meiji Holdings Co., Ltd.'s geographic revenue mix?
While specific details on Meiji Holdings Co., Ltd.'s geographic revenue mix are not available in the provided data, the company operates both in Japan and internationally. A significant portion of its revenue is likely generated from the domestic Japanese market, where it has a strong brand presence and extensive distribution network. Meiji is also expanding its presence in international markets, particularly in Asia, which is expected to contribute to future revenue growth. Investors should seek additional information on the company's geographic revenue mix to assess its exposure to different markets and regions.
What are the key factors to evaluate for MEJHF?
Meiji Holdings Co., Ltd. (MEJHF) currently holds an AI score of 54/100, indicating moderate score. Key strength: Diversified product portfolio across food and pharmaceutical sectors.. Primary risk to monitor: Ongoing: Intense competition from other food and pharmaceutical companies, impacting market share and profitability.. This is not financial advice.
How frequently does MEJHF data refresh on this page?
MEJHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MEJHF's recent stock price performance?
Recent price movement in Meiji Holdings Co., Ltd. (MEJHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across food and pharmaceutical sectors.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MEJHF overvalued or undervalued right now?
Determining whether Meiji Holdings Co., Ltd. (MEJHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.